SlideShare a Scribd company logo
1 of 29
Download to read offline
Intro to Health
Technology
Assessment
Cathal Walsh
Centre for Health Decision Science (HRB)
@CHeDS_ie
Biostatistician (NCPE) - Chair of Statistics (UL)
Decision Making
Question
Information Values
A set of
recommended
treatments
Health Technology
Assessment
• In theory, HTA provides a structured
framework for decision making.
• The framework used in Ireland is similar
to that employed in the UK and uses the
QALY and cost tradeoff.
Decision Making … the QALY
• The quality adjusted life year (QALY) is a
function of quality and duration of life.
This is best illustrated by a sketch …
• Note that it explicitly trades side effects,
disability and inconvenience of treatment
(etc!) against outcomes.
Tx 1 (Sustained)
Tx 2 (+efficacy, waning.)
Notes on the QALY
• In theory we can compare in an
equitable fashion across disease areas.
• This allows consideration of the impact
of interventions in a fair way and in a
univariate fashion.
• Thus a perfect ranking of interventions
can be obtained.
Decision Making - the C/E
plane
• The cost effectiveness plane is a core
aspect of how outcomes are
communicated and interpreted. It trades
off gains in health outcomes (on the x-
axis) and costs (on the y-axis).
Simple Decisions ... ?
*
++ Health
++ Investment
*
**
Simple Decisions ... ?
(Q,C) Do It
++ Health
++ Investment
Simple Decisions ... ?
(Q,C)
Don’t do It
Simple Decisions ... ?
(Q,C)
Put it on the
list of things to
do …
Simple Decisions ... ?
(Q,C)
Put it on the
list of things to
do …
ICER
Simple Decisions ... ?
Simple Decisions ... ?
Simple Decisions ... ?
Simple Decisions ... ?
Simple Decisions ... ?
*
++ Health
++ Investment
*
**
The Threshold … The Theory
ICER < 45k / Q good
ICER > 45k / Q bad
Simple Decisions ... ?
*
++ Health
++ Investment
*
**
The Threshold … The Theory
BUT … why use 45k?
The Threshold … The Theory
Utilisation
ProspectiveThreshold
The Threshold … The Theory
Utilisation
ProspectiveThreshold
The Threshold … Estimation in Practice
• What is the cost per QALY of the things
we stop doing to afford the new things?
• What is the cost per QALY of the things
we should stop doing to afford the new
things?
• On average, what is the marginal cost
per QALY in our health system?
The Threshold … Estimation in Practice
• What is the cost per QALY of the things
we stop doing to afford the new things?
• What is the cost per QALY of the things
we should stop doing to afford the new
things?
• On average, what is the marginal cost
per QALY in our health system?
Inefficiencies
Disinvestment
Practical Assessment
(Data?!)
Other considerations
• The Value set we use.
• The Uncertainty associated with the
parameters.
• The comparators used in the models.
• Indications for treatment.
• Structural uncertainty in models.
• Societal vs healthcare payer perspective.
Workarounds (Fudges)
• QALY loadings.
• Disease specific threshold.
• Selective alternative perspectives.
• Ring fenced budgets for selected
conditions.
• Differential discounting.
• MCDA (perhaps?).
Multi Criteria Decision
Analysis
• Affects the Value side alone.
• Allows explicit incorporation of other
factors into the value function.
• Strictly speaking cost per QALY is a form
of MCDA.
• Cannot change the budget available –
just the ordering of the interventions we
fund.
What do we do now?
• An ‘informal’ MCDA approach.
• A 45,000 / QALY ‘initial’ threshold.
• Reimbursement occurs for some
interventions above this level.
• A process for broader consideration of
the decision exists.
Exercise

More Related Content

What's hot

Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...Office of Health Economics
 
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...TransCelerate
 
ECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
 
Mini-Course Starter Kits
Mini-Course Starter KitsMini-Course Starter Kits
Mini-Course Starter KitsEUPATI
 
Ispor do nice_decisions_affect_decisions_in_other_countries
Ispor do nice_decisions_affect_decisions_in_other_countriesIspor do nice_decisions_affect_decisions_in_other_countries
Ispor do nice_decisions_affect_decisions_in_other_countriesOffice of Health Economics
 
Adaptive pathways intro_ispor_second_plenary_nov14
Adaptive pathways intro_ispor_second_plenary_nov14Adaptive pathways intro_ispor_second_plenary_nov14
Adaptive pathways intro_ispor_second_plenary_nov14Office of Health Economics
 
Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...HTAi Bilbao 2012
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...Office of Health Economics
 
A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)
A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)
A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)Canadian Organization for Rare Disorders
 
Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.
Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.
Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.IMSTA
 
Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...
Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...
Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...Office of Health Economics
 
Evaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomesEvaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomescheweb1
 
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015Office of Health Economics
 
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Office of Health Economics
 
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Office of Health Economics
 

What's hot (20)

Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...Operationalising Value-based Pricing: Do we know what we value and what we ar...
Operationalising Value-based Pricing: Do we know what we value and what we ar...
 
RDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory UpdateRDD 2020 Day 1 PM: Health Canada Regulatory Update
RDD 2020 Day 1 PM: Health Canada Regulatory Update
 
HTA's 'Macro' Role in Health Care Systems
HTA's 'Macro' Role in Health Care SystemsHTA's 'Macro' Role in Health Care Systems
HTA's 'Macro' Role in Health Care Systems
 
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
TransCelerate Overview - Interpretation of Pharmacovigilance Regulations Init...
 
Ian Burgess
Ian BurgessIan Burgess
Ian Burgess
 
ECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
ECO 11: Medicines Optimisation in Northern Ireland - Frans van Andel
 
Mini-Course Starter Kits
Mini-Course Starter KitsMini-Course Starter Kits
Mini-Course Starter Kits
 
Ispor do nice_decisions_affect_decisions_in_other_countries
Ispor do nice_decisions_affect_decisions_in_other_countriesIspor do nice_decisions_affect_decisions_in_other_countries
Ispor do nice_decisions_affect_decisions_in_other_countries
 
Adaptive pathways intro_ispor_second_plenary_nov14
Adaptive pathways intro_ispor_second_plenary_nov14Adaptive pathways intro_ispor_second_plenary_nov14
Adaptive pathways intro_ispor_second_plenary_nov14
 
Managed Entry Agreements in Asia
Managed Entry Agreements in Asia Managed Entry Agreements in Asia
Managed Entry Agreements in Asia
 
Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...Health Technology Assessment (HTA) Report: Interventions to increase particip...
Health Technology Assessment (HTA) Report: Interventions to increase particip...
 
Ispor opportunity costs_sks
Ispor opportunity costs_sksIspor opportunity costs_sks
Ispor opportunity costs_sks
 
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
How can HTA’s in Asia respond to Increased Clinical Uncertainty: the potentia...
 
A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)
A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)
A Joint Approach to Value-based Access for Public Drug Plans: Imran Ali (pCPA)
 
Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.
Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.
Dr Brenda Dooley, Managing Director, AXIS Healthcare Consulting Ltd.
 
Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...
Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...
Comparing Cancer-Specific Preference-Based Outcome Measures: The Same but Dif...
 
Evaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomesEvaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomes
 
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015Lunchtime Seminar with Paula Lorgelly - 14 December 2015
Lunchtime Seminar with Paula Lorgelly - 14 December 2015
 
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
Why RWE Matters to Payers: Incorporating RWE in Health Economic Analysis to M...
 
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
Presentation by Paula Lorgelly - Beyond QALYs: A Quantum Leap Forward or a Le...
 

Similar to HTA Training - Prof Cathal Walsh - March 27th 2015

An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...Carmen Figueroa
 
Health economic evaluation for the NHS workshop
Health economic evaluation for the NHS workshopHealth economic evaluation for the NHS workshop
Health economic evaluation for the NHS workshopInnovation Agency
 
2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roi2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roiGreg Fell
 
Apr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgApr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgOffice of Health Economics
 
Improving clinical services: no magic bullet... some things work better than ...
Improving clinical services: no magic bullet... some things work better than ...Improving clinical services: no magic bullet... some things work better than ...
Improving clinical services: no magic bullet... some things work better than ...NIHR CLAHRC West Midlands
 
PHARMACOECONOMIC_STUDIES..ppt
PHARMACOECONOMIC_STUDIES..pptPHARMACOECONOMIC_STUDIES..ppt
PHARMACOECONOMIC_STUDIES..pptashfaq22
 
Application of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICEApplication of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICEOffice of Health Economics
 
Fundamentals of Health Economics - Final Presentation.pptx
Fundamentals of Health Economics - Final Presentation.pptxFundamentals of Health Economics - Final Presentation.pptx
Fundamentals of Health Economics - Final Presentation.pptxMohsin Hassan Alvi
 
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisPharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisMohammed Mohammed
 
Modeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiesModeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiescheweb1
 
Excel in Health: Proposition
Excel in Health: PropositionExcel in Health: Proposition
Excel in Health: PropositionInnovation Agency
 
OneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHS
OneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHSOneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHS
OneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHSOxbridge Biotech Roundtable
 
Czarnitzki - Towards a portfolio of additionaliyu indicators
Czarnitzki - Towards a portfolio of additionaliyu indicatorsCzarnitzki - Towards a portfolio of additionaliyu indicators
Czarnitzki - Towards a portfolio of additionaliyu indicatorsinnovationoecd
 
Improving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesImproving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesOffice of Health Economics
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014GlobalResearchUCSF
 
Diagnosing Healthcare
Diagnosing HealthcareDiagnosing Healthcare
Diagnosing HealthcareMartin Hedley
 
Implementation Strategies & Outcomes: Advancing the Science
Implementation Strategies & Outcomes: Advancing the ScienceImplementation Strategies & Outcomes: Advancing the Science
Implementation Strategies & Outcomes: Advancing the ScienceHopkinsCFAR
 

Similar to HTA Training - Prof Cathal Walsh - March 27th 2015 (20)

An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...An introduction to using cost-effectiveness analysis to inform spending decis...
An introduction to using cost-effectiveness analysis to inform spending decis...
 
Health economic evaluation for the NHS workshop
Health economic evaluation for the NHS workshopHealth economic evaluation for the NHS workshop
Health economic evaluation for the NHS workshop
 
2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roi2 gf h econ cost effectivness and roi
2 gf h econ cost effectivness and roi
 
Apr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgApr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mg
 
Improving clinical services: no magic bullet... some things work better than ...
Improving clinical services: no magic bullet... some things work better than ...Improving clinical services: no magic bullet... some things work better than ...
Improving clinical services: no magic bullet... some things work better than ...
 
An Introduction to Health Economics
An Introduction to Health EconomicsAn Introduction to Health Economics
An Introduction to Health Economics
 
PHARMACOECONOMIC_STUDIES..ppt
PHARMACOECONOMIC_STUDIES..pptPHARMACOECONOMIC_STUDIES..ppt
PHARMACOECONOMIC_STUDIES..ppt
 
Application of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICEApplication of EQ-5D in Reimbursement Decision Making: The Case of NICE
Application of EQ-5D in Reimbursement Decision Making: The Case of NICE
 
Fundamentals of Health Economics - Final Presentation.pptx
Fundamentals of Health Economics - Final Presentation.pptxFundamentals of Health Economics - Final Presentation.pptx
Fundamentals of Health Economics - Final Presentation.pptx
 
Reflections_on_VBP_AKT_June2015
Reflections_on_VBP_AKT_June2015Reflections_on_VBP_AKT_June2015
Reflections_on_VBP_AKT_June2015
 
Pharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysisPharmacoeconomics Cost utility analysis
Pharmacoeconomics Cost utility analysis
 
Modeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policiesModeling the cost effectiveness of two big league pay-for-performance policies
Modeling the cost effectiveness of two big league pay-for-performance policies
 
Excel in Health: Proposition
Excel in Health: PropositionExcel in Health: Proposition
Excel in Health: Proposition
 
OneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHS
OneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHSOneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHS
OneStart 2015 London Bootcamp: Eli Gajraj, NICE - Gatekeeper to the NHS
 
Czarnitzki - Towards a portfolio of additionaliyu indicators
Czarnitzki - Towards a portfolio of additionaliyu indicatorsCzarnitzki - Towards a portfolio of additionaliyu indicators
Czarnitzki - Towards a portfolio of additionaliyu indicators
 
Improving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesImproving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent Technologies
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
 
Diagnosing Healthcare
Diagnosing HealthcareDiagnosing Healthcare
Diagnosing Healthcare
 
DRPH1.ppt
DRPH1.pptDRPH1.ppt
DRPH1.ppt
 
Implementation Strategies & Outcomes: Advancing the Science
Implementation Strategies & Outcomes: Advancing the ScienceImplementation Strategies & Outcomes: Advancing the Science
Implementation Strategies & Outcomes: Advancing the Science
 

More from ipposi

PPI Landscape in Ireland - IPPOSI perspective
PPI Landscape in Ireland - IPPOSI perspectivePPI Landscape in Ireland - IPPOSI perspective
PPI Landscape in Ireland - IPPOSI perspectiveipposi
 
Investing in Patient Education to support PPI_v1.1.pptx
Investing in Patient Education to support PPI_v1.1.pptxInvesting in Patient Education to support PPI_v1.1.pptx
Investing in Patient Education to support PPI_v1.1.pptxipposi
 
2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europe2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europeipposi
 
November 2023 Industry Round Table - Sessions 1 and 2
November 2023 Industry Round Table - Sessions 1 and 2November 2023 Industry Round Table - Sessions 1 and 2
November 2023 Industry Round Table - Sessions 1 and 2ipposi
 
National approaches to Electronic Health Records
National approaches to Electronic Health RecordsNational approaches to Electronic Health Records
National approaches to Electronic Health Recordsipposi
 
Derick Mitchell_Biobanking from the patient perspective.pdf
Derick Mitchell_Biobanking from the patient perspective.pdfDerick Mitchell_Biobanking from the patient perspective.pdf
Derick Mitchell_Biobanking from the patient perspective.pdfipposi
 
Health data sharing from patients' perspective
Health data sharing from patients' perspectiveHealth data sharing from patients' perspective
Health data sharing from patients' perspectiveipposi
 
Mental Health - Leading the data sharing charge with a rights-based approach
Mental Health - Leading the data sharing charge with a rights-based approachMental Health - Leading the data sharing charge with a rights-based approach
Mental Health - Leading the data sharing charge with a rights-based approachipposi
 
Health Information Framework for Ireland
Health Information Framework for IrelandHealth Information Framework for Ireland
Health Information Framework for Irelandipposi
 
Clinical Workflow for Capture of Patient Registry Data
Clinical Workflow for Capture of Patient Registry DataClinical Workflow for Capture of Patient Registry Data
Clinical Workflow for Capture of Patient Registry Dataipposi
 
Health Data Sharing Scene Setting
Health Data Sharing Scene Setting Health Data Sharing Scene Setting
Health Data Sharing Scene Setting ipposi
 
EU Clinical Trials Regulation - IPPOSI perspective
EU Clinical Trials Regulation - IPPOSI perspectiveEU Clinical Trials Regulation - IPPOSI perspective
EU Clinical Trials Regulation - IPPOSI perspectiveipposi
 
Medtech QA/RA Conference - IPPOSI Presentation
Medtech QA/RA Conference - IPPOSI PresentationMedtech QA/RA Conference - IPPOSI Presentation
Medtech QA/RA Conference - IPPOSI Presentationipposi
 
Patient Centricity in Value-based healthcare, Sept 2022
Patient Centricity in Value-based healthcare, Sept 2022Patient Centricity in Value-based healthcare, Sept 2022
Patient Centricity in Value-based healthcare, Sept 2022ipposi
 
ISHG Presentation - IPPOSI Citizens' Jury on Genomics
ISHG Presentation - IPPOSI Citizens' Jury on GenomicsISHG Presentation - IPPOSI Citizens' Jury on Genomics
ISHG Presentation - IPPOSI Citizens' Jury on Genomicsipposi
 
2022 World Day Brain Event - IPPOSI Presentation
2022 World Day Brain Event - IPPOSI Presentation2022 World Day Brain Event - IPPOSI Presentation
2022 World Day Brain Event - IPPOSI Presentationipposi
 
2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentation2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentationipposi
 
Pharma Integrity Event - May 2022
Pharma Integrity Event - May 2022Pharma Integrity Event - May 2022
Pharma Integrity Event - May 2022ipposi
 
IPPOSI 2021-2024 strategy - membership engagement summary
IPPOSI 2021-2024 strategy - membership engagement summaryIPPOSI 2021-2024 strategy - membership engagement summary
IPPOSI 2021-2024 strategy - membership engagement summaryipposi
 
Carol Munt - 'patients as partners'
Carol Munt - 'patients as partners' Carol Munt - 'patients as partners'
Carol Munt - 'patients as partners' ipposi
 

More from ipposi (20)

PPI Landscape in Ireland - IPPOSI perspective
PPI Landscape in Ireland - IPPOSI perspectivePPI Landscape in Ireland - IPPOSI perspective
PPI Landscape in Ireland - IPPOSI perspective
 
Investing in Patient Education to support PPI_v1.1.pptx
Investing in Patient Education to support PPI_v1.1.pptxInvesting in Patient Education to support PPI_v1.1.pptx
Investing in Patient Education to support PPI_v1.1.pptx
 
2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europe2023 ISPOR Patient Representatives Roundtable - Europe
2023 ISPOR Patient Representatives Roundtable - Europe
 
November 2023 Industry Round Table - Sessions 1 and 2
November 2023 Industry Round Table - Sessions 1 and 2November 2023 Industry Round Table - Sessions 1 and 2
November 2023 Industry Round Table - Sessions 1 and 2
 
National approaches to Electronic Health Records
National approaches to Electronic Health RecordsNational approaches to Electronic Health Records
National approaches to Electronic Health Records
 
Derick Mitchell_Biobanking from the patient perspective.pdf
Derick Mitchell_Biobanking from the patient perspective.pdfDerick Mitchell_Biobanking from the patient perspective.pdf
Derick Mitchell_Biobanking from the patient perspective.pdf
 
Health data sharing from patients' perspective
Health data sharing from patients' perspectiveHealth data sharing from patients' perspective
Health data sharing from patients' perspective
 
Mental Health - Leading the data sharing charge with a rights-based approach
Mental Health - Leading the data sharing charge with a rights-based approachMental Health - Leading the data sharing charge with a rights-based approach
Mental Health - Leading the data sharing charge with a rights-based approach
 
Health Information Framework for Ireland
Health Information Framework for IrelandHealth Information Framework for Ireland
Health Information Framework for Ireland
 
Clinical Workflow for Capture of Patient Registry Data
Clinical Workflow for Capture of Patient Registry DataClinical Workflow for Capture of Patient Registry Data
Clinical Workflow for Capture of Patient Registry Data
 
Health Data Sharing Scene Setting
Health Data Sharing Scene Setting Health Data Sharing Scene Setting
Health Data Sharing Scene Setting
 
EU Clinical Trials Regulation - IPPOSI perspective
EU Clinical Trials Regulation - IPPOSI perspectiveEU Clinical Trials Regulation - IPPOSI perspective
EU Clinical Trials Regulation - IPPOSI perspective
 
Medtech QA/RA Conference - IPPOSI Presentation
Medtech QA/RA Conference - IPPOSI PresentationMedtech QA/RA Conference - IPPOSI Presentation
Medtech QA/RA Conference - IPPOSI Presentation
 
Patient Centricity in Value-based healthcare, Sept 2022
Patient Centricity in Value-based healthcare, Sept 2022Patient Centricity in Value-based healthcare, Sept 2022
Patient Centricity in Value-based healthcare, Sept 2022
 
ISHG Presentation - IPPOSI Citizens' Jury on Genomics
ISHG Presentation - IPPOSI Citizens' Jury on GenomicsISHG Presentation - IPPOSI Citizens' Jury on Genomics
ISHG Presentation - IPPOSI Citizens' Jury on Genomics
 
2022 World Day Brain Event - IPPOSI Presentation
2022 World Day Brain Event - IPPOSI Presentation2022 World Day Brain Event - IPPOSI Presentation
2022 World Day Brain Event - IPPOSI Presentation
 
2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentation2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentation
 
Pharma Integrity Event - May 2022
Pharma Integrity Event - May 2022Pharma Integrity Event - May 2022
Pharma Integrity Event - May 2022
 
IPPOSI 2021-2024 strategy - membership engagement summary
IPPOSI 2021-2024 strategy - membership engagement summaryIPPOSI 2021-2024 strategy - membership engagement summary
IPPOSI 2021-2024 strategy - membership engagement summary
 
Carol Munt - 'patients as partners'
Carol Munt - 'patients as partners' Carol Munt - 'patients as partners'
Carol Munt - 'patients as partners'
 

Recently uploaded

Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxDr. Rabia Inam Gandapore
 
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdfDr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdfSumathi Arumugam
 
Test bank for critical care nursing a holistic approach 11th edition morton f...
Test bank for critical care nursing a holistic approach 11th edition morton f...Test bank for critical care nursing a holistic approach 11th edition morton f...
Test bank for critical care nursing a holistic approach 11th edition morton f...robinsonayot
 
Intro to disinformation and public health
Intro to disinformation and public healthIntro to disinformation and public health
Intro to disinformation and public healthTina Purnat
 
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptxHISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptxDhanashri Prakash Sonavane
 
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATROMOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATROKanhu Charan
 
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...deepakkumar115120
 
ABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancyABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancyMs. Sapna Pal
 
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsCirculatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsMedicoseAcademics
 
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...bkling
 
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxCreeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxYasser Alzainy
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxMohammadAbuzar19
 
Physicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdfPhysicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdfRAJ K. MAURYA
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesMedicoseAcademics
 
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana GuptaLifecare Centre
 
The Clean Living Project Episode 23 - Journaling
The Clean Living Project Episode 23 - JournalingThe Clean Living Project Episode 23 - Journaling
The Clean Living Project Episode 23 - JournalingThe Clean Living Project
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan 087776558899
 
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdfShazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdfTrustlife
 
Part I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happenedPart I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happenedbkling
 
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxSwetaba Besh
 

Recently uploaded (20)

Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptx
 
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdfDr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
Dr. A Sumathi - LINEARITY CONCEPT OF SIGNIFICANCE.pdf
 
Test bank for critical care nursing a holistic approach 11th edition morton f...
Test bank for critical care nursing a holistic approach 11th edition morton f...Test bank for critical care nursing a holistic approach 11th edition morton f...
Test bank for critical care nursing a holistic approach 11th edition morton f...
 
Intro to disinformation and public health
Intro to disinformation and public healthIntro to disinformation and public health
Intro to disinformation and public health
 
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptxHISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
HISTORY, CONCEPT AND ITS IMPORTANCE IN DRUG DEVELOPMENT.pptx
 
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATROMOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
MOTION MANAGEMANT IN LUNG SBRT BY DR KANHU CHARAN PATRO
 
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
VIP ℂall Girls Kothanur {{ Bangalore }} 6378878445 WhatsApp: Me 24/7 Hours Se...
 
ABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancyABO Blood grouping in-compatibility in pregnancy
ABO Blood grouping in-compatibility in pregnancy
 
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsCirculatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanisms
 
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
See it and Catch it! Recognizing the Thought Traps that Negatively Impact How...
 
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptxCreeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
Creeping Stroke - Venous thrombosis presenting with pc-stroke.pptx
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptx
 
Physicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdfPhysicochemical properties (descriptors) in QSAR.pdf
Physicochemical properties (descriptors) in QSAR.pdf
 
Difference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac MusclesDifference Between Skeletal Smooth and Cardiac Muscles
Difference Between Skeletal Smooth and Cardiac Muscles
 
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
 
The Clean Living Project Episode 23 - Journaling
The Clean Living Project Episode 23 - JournalingThe Clean Living Project Episode 23 - Journaling
The Clean Living Project Episode 23 - Journaling
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
 
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdfShazia Iqbal 2024 - Bioorganic Chemistry.pdf
Shazia Iqbal 2024 - Bioorganic Chemistry.pdf
 
Part I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happenedPart I - Anticipatory Grief: Experiencing grief before the loss has happened
Part I - Anticipatory Grief: Experiencing grief before the loss has happened
 
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptxANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF REPRODUCTIVE SYSTEM.pptx
 

HTA Training - Prof Cathal Walsh - March 27th 2015

  • 1. Intro to Health Technology Assessment Cathal Walsh Centre for Health Decision Science (HRB) @CHeDS_ie Biostatistician (NCPE) - Chair of Statistics (UL)
  • 2. Decision Making Question Information Values A set of recommended treatments
  • 3. Health Technology Assessment • In theory, HTA provides a structured framework for decision making. • The framework used in Ireland is similar to that employed in the UK and uses the QALY and cost tradeoff.
  • 4. Decision Making … the QALY • The quality adjusted life year (QALY) is a function of quality and duration of life. This is best illustrated by a sketch … • Note that it explicitly trades side effects, disability and inconvenience of treatment (etc!) against outcomes.
  • 5. Tx 1 (Sustained) Tx 2 (+efficacy, waning.)
  • 6. Notes on the QALY • In theory we can compare in an equitable fashion across disease areas. • This allows consideration of the impact of interventions in a fair way and in a univariate fashion. • Thus a perfect ranking of interventions can be obtained.
  • 7. Decision Making - the C/E plane • The cost effectiveness plane is a core aspect of how outcomes are communicated and interpreted. It trades off gains in health outcomes (on the x- axis) and costs (on the y-axis).
  • 8. Simple Decisions ... ? * ++ Health ++ Investment * **
  • 9. Simple Decisions ... ? (Q,C) Do It ++ Health ++ Investment
  • 10. Simple Decisions ... ? (Q,C) Don’t do It
  • 11. Simple Decisions ... ? (Q,C) Put it on the list of things to do …
  • 12. Simple Decisions ... ? (Q,C) Put it on the list of things to do … ICER
  • 17. Simple Decisions ... ? * ++ Health ++ Investment * **
  • 18. The Threshold … The Theory ICER < 45k / Q good ICER > 45k / Q bad
  • 19. Simple Decisions ... ? * ++ Health ++ Investment * **
  • 20. The Threshold … The Theory BUT … why use 45k?
  • 21. The Threshold … The Theory Utilisation ProspectiveThreshold
  • 22. The Threshold … The Theory Utilisation ProspectiveThreshold
  • 23. The Threshold … Estimation in Practice • What is the cost per QALY of the things we stop doing to afford the new things? • What is the cost per QALY of the things we should stop doing to afford the new things? • On average, what is the marginal cost per QALY in our health system?
  • 24. The Threshold … Estimation in Practice • What is the cost per QALY of the things we stop doing to afford the new things? • What is the cost per QALY of the things we should stop doing to afford the new things? • On average, what is the marginal cost per QALY in our health system? Inefficiencies Disinvestment Practical Assessment (Data?!)
  • 25. Other considerations • The Value set we use. • The Uncertainty associated with the parameters. • The comparators used in the models. • Indications for treatment. • Structural uncertainty in models. • Societal vs healthcare payer perspective.
  • 26. Workarounds (Fudges) • QALY loadings. • Disease specific threshold. • Selective alternative perspectives. • Ring fenced budgets for selected conditions. • Differential discounting. • MCDA (perhaps?).
  • 27. Multi Criteria Decision Analysis • Affects the Value side alone. • Allows explicit incorporation of other factors into the value function. • Strictly speaking cost per QALY is a form of MCDA. • Cannot change the budget available – just the ordering of the interventions we fund.
  • 28. What do we do now? • An ‘informal’ MCDA approach. • A 45,000 / QALY ‘initial’ threshold. • Reimbursement occurs for some interventions above this level. • A process for broader consideration of the decision exists.